Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| MODERNA | 7 | 16 | +0,59 % | ||
| BIOGEN | 6 | 54 | +1,02 % | ||
| ARROWHEAD PHARMACEUTICALS | 3 | - | +2,38 % | ||
| OMNIAB | 3 | - | 0,00 % | ||
| BIONTECH | 2 | 13 | -0,36 % | ||
| DISC MEDICINE | 2 | 7 | 0,00 % | ||
| INTRA-CELLULAR THERAPIES | 2 | 6 | -1,63 % | ||
| ZAI LAB LTD ADR | 2 | 6 | -2,34 % | ||
| INTELLIA THERAPEUTICS | 2 | 5 | -0,61 % | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2 | 3 | -7,78 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:12 | PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider | 6 | GlobeNewswire (USA) | ||
| 15:06 | Where Legend Biotech Stands With Analysts | 3 | Benzinga.com | ||
| 14:42 | Galapagos downgraded by Barclays, PT cut to €22 | 3 | Investing.com | ||
| 14:34 | Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why | 1 | Zacks | ||
| 14:30 | Guardant Reveal aids organ preservation in rectal cancer treatment | 1 | Investing.com | ||
| 14:18 | Biogen Says FDA And EMA Accept Applications For Higher Dose Regimen Of Nusinersen In SMA | 135 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European... ► Artikel lesen | |
| 14:18 | Amneal gains FDA approval for dementia and oncology drugs | 1 | Investing.com | ||
| 14:15 | Is Larry Ellison Moderna's Saving Grace? Is Moderna Stock Now A Buy? | 19 | Investor's Business Daily | ||
| 14:06 | Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 6 | Benzinga.com | ||
| 13:58 | FDA und EMA prüfen höhere Dosis von Biogens SMA-Medikament | 3 | Investing.com Deutsch | ||
| 13:46 | Biogen Inc.: FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA | 138 | GlobeNewswire (Europe) | Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan.... ► Artikel lesen | |
| 13:46 | BridgeBio's Neil Kumar on an underdog drug launch and wooing deal-hungry investors | 2 | BioPharma Dive | ||
| 13:42 | FDA and EMA review Biogen's higher dose SMA drug | 4 | Investing.com | ||
| 13:26 | Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? | 4 | Insider Monkey | ||
| 13:26 | Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now? | 1 | Insider Monkey | ||
| 13:26 | Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? | 1 | Insider Monkey | ||
| 13:26 | Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? | 1 | Insider Monkey | ||
| 13:26 | Why Is Andreas Halvorsen Bullish On Roivant Sciences Ltd. (ROIV) Now? | 1 | Insider Monkey | ||
| 13:18 | Beam Therapeutics to present updated BEAM-101 trial data | 4 | Investing.com | ||
| 13:14 | Aktienmarkt: Kurs der Sanofi SA-Aktie im Plus (100,60 €) | 222 | ARIVA.de | Die Aktie von Sanofi SA notiert heute fester. Der jüngste Kurs betrug 100,60 Euro. Ein Wertanstieg von 1,75 Prozent steht gegenwärtig für die Aktie von Sanofi SA zu Buche. Das Papier verteuerte sich... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
